Earnings Summary

Mersana Therapeutics Inc’s revenue jumped 148.69% since last year same period to $10.65Mn in the Q2 2023. On a quarterly growth basis, Mersana Therapeutics Inc has generated 36.55% jump in its revenue since last 3-months.

Mersana Therapeutics Inc’s net profit fell -4% since last year same period to $-54.31Mn in the Q2 2023. On a quarterly growth basis, Mersana Therapeutics Inc has generated 3.3% jump in its net profits since last 3-months.

Mersana Therapeutics Inc’s net profit margin jumped 58.18% since last year same period to -509.73% in the Q2 2023. On a quarterly growth basis, Mersana Therapeutics Inc has generated 29.19% jump in its net profit margins since last 3-months.

Mersana Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.54 - a -500% fall from last quarter’s estimates.

Mersana Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.54.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Mersana Therapeutics Inc’s return on assets (ROA) stands at -0.49.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Mersana Therapeutics Inc’s return on equity (ROE) stands at -1.92.